Sage Therapeutics Yönetim
Yönetim kriter kontrolleri 1/4
Sage Therapeutics CEO'su Barry Greene, Dec2020 tarihinde atandı, in görev süresi 3.92 yıldır. in toplam yıllık tazminatı $ 6.24M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.8% maaş ve 87.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.14% ine doğrudan sahiptir ve bu hisseler $ 417.68K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 9.3 yıldır.
Anahtar bilgiler
Barry Greene
İcra Kurulu Başkanı
US$6.2m
Toplam tazminat
CEO maaş yüzdesi | 12.8% |
CEO görev süresi | 3.9yrs |
CEO sahipliği | 0.1% |
Yönetim ortalama görev süresi | 1.3yrs |
Yönetim Kurulu ortalama görev süresi | 9.3yrs |
Son yönetim güncellemeleri
Recent updates
CNS Drug Development: Same As It Ever Was
Nov 19Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Oct 07Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge
Aug 30Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
Jul 25Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price
Jul 13Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
May 30Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
May 21Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
Feb 22Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Feb 15Sizing Up Sage Therapeutics
Jan 22Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Aug 09Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Feb 22An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Nov 12Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Oct 14Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Aug 02We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Jun 15Sage Therapeutics: Well-Funded But Uninspiring Data
Mar 24We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Feb 26Sage Therapeutics: Biogen's Backing May See It Through
Jan 04What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today
Aug 05CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$338m |
Jun 30 2024 | n/a | n/a | -US$446m |
Mar 31 2024 | n/a | n/a | -US$503m |
Dec 31 2023 | US$6m | US$799k | -US$541m |
Sep 30 2023 | n/a | n/a | -US$656m |
Jun 30 2023 | n/a | n/a | -US$592m |
Mar 31 2023 | n/a | n/a | -US$558m |
Dec 31 2022 | US$6m | US$761k | -US$533m |
Sep 30 2022 | n/a | n/a | -US$510m |
Jun 30 2022 | n/a | n/a | -US$503m |
Mar 31 2022 | n/a | n/a | -US$484m |
Dec 31 2021 | US$59m | US$735k | -US$458m |
Sep 30 2021 | n/a | n/a | US$642m |
Jun 30 2021 | n/a | n/a | US$666m |
Mar 31 2021 | n/a | n/a | US$637m |
Dec 31 2020 | US$836k | US$53k | US$606m |
Tazminat ve Piyasa: Barry 'nin toplam tazminatı ($USD 6.24M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.24M ).
Tazminat ve Kazançlar: Barry şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Barry Greene (61 yo)
3.9yrs
Görev süresi
US$6,237,491
Tazminat
Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and its Director since October 1, 2020. Mr. Greene joined the Sage Therapeutics, Inc....
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
President | 3.9yrs | US$6.24m | 0.14% $ 417.7k | |
Chief Operating Officer | no data | US$2.28m | 0.0081% $ 24.5k | |
Chief Medical Officer | 2.1yrs | US$1.27m | 0.018% $ 52.7k | |
Chief Scientific Officer | 1.3yrs | Veri yok | Veri yok | |
Director of Investor Relations | no data | Veri yok | Veri yok | |
Senior VP & General Counsel | no data | Veri yok | Veri yok | |
VP & Head of People | less than a year | Veri yok | Veri yok | |
Senior Vice President of Drug Safety & Pharmacovigilance | no data | Veri yok | Veri yok | |
Senior Vice President of Corporate Affairs | 3yrs | Veri yok | Veri yok | |
Medical Director of Early Clinical Development | no data | Veri yok | Veri yok | |
Senior Analyst of Investor Relation | no data | Veri yok | Veri yok | |
Investor Contact | no data | Veri yok | Veri yok |
1.3yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: SAGE 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
President | 4.1yrs | US$6.24m | 0.14% $ 417.7k | |
Independent Director | 10.2yrs | US$440.05k | 0% $ 0 | |
Independent Director | 10.5yrs | US$435.05k | 0.0046% $ 14.0k | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Independent Chair of the Board | 8.3yrs | US$417.55k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
9.3yrs
Ortalama Görev Süresi
63yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: SAGE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.3 yıldır).